Literature DB >> 7499876

Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism.

A A Vandenbark1, B Celnik, M Vainiene, S D Miller, H Offner.   

Abstract

Mechanisms of adult tolerance induced by injecting myelin Ag/ECDI (ethyl carbodiimide)-coupled splenocytes (Ag-SPL) were evaluated in Lewis rat experimental autoimmune encephalomyelitis (EAE). Rats could be tolerized against the major encephalitogenic epitope of guinea pig basic protein (Gp-BP), residues 72-89, using either S72-89-SPL or crude spinal cord homogenate (SCH)-SPL. In contrast to lymph node responses that were not affected significantly, the proliferation responses of blood T cells were markedly inhibited at the peak of EAE and during the recovery period to both Gp-BP and S72-89, but not to purified protein derivative (PPD), demonstrating Ag-specific tolerance. Tolerance induction reduced the number of infiltrating spinal cord (SC) cells, especially recruited CD45RC+ cells, as well as SC proliferation responses to S72-89 throughout the course of EAE. In contrast, SC response to PPD was increased at onset of EAE, but later during recovery the PPD response was also decreased compared with control rats. Tolerance induced by S72-89-SPL in blood and SC T cells could be reversed by incubation in IL-2, in accordance with an anergy model. BP-specific T cells preincubated in vitro with Gp-BP-SPL were rendered unresponsive to Gp-BP or S72-89, compared with the same T cells preincubated with histone (Hist)-SPL that remained Ag responsive. Consistent with an anergy model, preincubation with BP-SPL+IL-2 partially prevented tolerance induction to BP. T cells tolerized in vitro to BP-SPL induced milder EAE with delayed onset compared with control-tolerized T cells that produced lethal disease. These results demonstrate the efficacy of myelin Ag-coupled SPL in preventing EAE by selective tolerization of encephalitogenic T cells through a partially reversible anergy-induction mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499876

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes.

Authors:  Urs Christen; Kurt H Edelmann; Dorian B McGavern; Tom Wolfe; Bryan Coon; Meghann K Teague; Stephen D Miller; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 2.  Immune Tolerance for Autoimmune Disease and Cell Transplantation.

Authors:  Xunrong Luo; Stephen D Miller; Lonnie D Shea
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

3.  Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells.

Authors:  H Offner; R Jacobs; B F Bebo; A A Vandenbark
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation.

Authors:  Andrew Jones; Daniel Hawiger
Journal:  Front Immunol       Date:  2017-05-09       Impact factor: 7.561

Review 5.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

6.  Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice.

Authors:  Lanfang Zhang; Yixian Guo; Chang-Qing Xia
Journal:  J Immunol Res       Date:  2015-07-14       Impact factor: 4.818

Review 7.  Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Courtney A Iberg; Daniel Hawiger
Journal:  Antibodies (Basel)       Date:  2020-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.